Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;118:S_815

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Aubert, R. E
Right arrow Articles by Flockhart, D. A
PubMed
Right arrow Articles by Aubert, R. E
Right arrow Articles by Flockhart, D. A

(Circulation. 2008;118:S_815.)
© 2008 American Heart Association, Inc.


Understanding Variability in Antiplatelet Drug Effects in Acute Coronary Syndromes

Abstract 3998: Proton Pump Inhibitors Effect on Clopidogrel Effectiveness: The Clopidogrel Medco Outcomes Study

Ronald E Aubert1; Robert S Epstein1; J R Teagarden1; Fang Xia1; Jianying Yao1; Zeruesenay Desta2; Todd Skaar2; David A Flockhart2

1 Medco Health Solutions, Inc., Franklin Lakes, NJ
2 Indiana Univ, Indianapolis, IN

Background: The anti-platelet properties of clopidogrel are thought to be activated by cytochrome P450 2C19. This isoenzyme is potently inhibited by the most commonly prescribed proton pump inhibitors (PPIs) and therefore may interfere with clopidogrel activation and its anti-platelet effects.

Methods: We investigated the potential impact of PPIs on the effectiveness of clopidogrel to prevent coronary artery stent re-stenosis through a retrospective cohort study using the National Medco Integrated Database file, which covers approximately 19 million lives. We selected patients who underwent stent placement at sometime during a one-year period in 2005–2006, who started taking clopidogrel at the time of stent placement, and who were at least 80% compliant during the ensuing year (n=14,383). We followed these patients for the one-year incidence of major adverse CV events: hospitalization for stroke, MI, angina or CABG. We compared those who took clopidogrel alone (n=9862) vs. those who took clopidogrel with PPIs (n=4521), adjusting for baseline differences in age, gender and comorbidity.

Results: Stent patients with no preceding CV events taking PPIs with clopidogrel showed a 32.5% incidence of a major CV event within one year vs. 21.2% of patients not taking PPIs (adjusted OR 1.79, CI 1.62–1.97). A more pronounced effect was seen among patients with a preceding CV event; 39.8% vs 26.2% (adjusted OR of 1.86, CI 1.63–2.12).

Conclusions: Our findings suggest that the drug interaction between PPIs and clopidogrel may result in serious adverse outcomes within one year of therapy initiation, and further support investigations into the effects of cytochrome P450 2C19 genetic polymorphisms.




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
E. J. Last and A. H. Sheehan
Review of recent evidence: Potential interaction between clopidogrel and proton pump inhibitors
Am. J. Health Syst. Pharm., December 1, 2009; 66(23): 2117 - 2122.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
C. Varenhorst, S. James, D. Erlinge, J. T. Brandt, O. O. Braun, M. Man, A. Siegbahn, J. Walker, L. Wallentin, K. J. Winters, et al.
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
Eur. Heart J., July 2, 2009; 30(14): 1744 - 1752.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
N. B Norgard, K. D Mathews, and G. C Wall
Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors
Ann. Pharmacother., July 1, 2009; 43(7): 1266 - 1274.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. M. Ho, T. M. Maddox, L. Wang, S. D. Fihn, R. L. Jesse, E. D. Peterson, and J. S. Rumsfeld
Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome
JAMA, March 4, 2009; 301(9): 937 - 944.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Aubert, R. E
Right arrow Articles by Flockhart, D. A
PubMed
Right arrow Articles by Aubert, R. E
Right arrow Articles by Flockhart, D. A